Effective albumin concentration and albumin function improve after long-term albumin therapy in patients with decompensated cirrhosis

2020 ◽  
Vol 52 ◽  
pp. e14
Author(s):  
M. Baldassarre ◽  
M. Tufoni ◽  
G. Zaccherini ◽  
D. Campion ◽  
F.G. Foschi ◽  
...  
Keyword(s):  
Decompensated Cirrhosis ◽  
Albumin Concentration ◽  
Albumin Therapy

Effective albumin concentration and albumin function improve after long-term albumin treatment in patients with decompensated cirrhosis

2020 ◽  
Vol 73 ◽  
pp. S211-S212
Author(s):  
Maurizio Baldassarre ◽  
Manuel Tufoni ◽  
Giacomo Zaccherini ◽  
Daniela Campion ◽  
Francesco Giuseppe Foschi ◽  
...  
Keyword(s):  
Decompensated Cirrhosis ◽  
Albumin Concentration

Long-Term Outcome After Antiviral Therapy of Patients With Hepatitis C Virus Infection and Decompensated Cirrhosis

2011 ◽  
Vol 9 (3) ◽  
pp. 249-253 ◽  
Author(s):  
Angelo Iacobellis ◽  
Francesco Perri ◽  
Maria Rosa Valvano ◽  
Nazario Caruso ◽  
Grazia Anna Niro ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Antiviral Therapy ◽  
Decompensated Cirrhosis ◽  
Hepatitis C Virus Infection ◽  
Term Outcome ◽  
Long Term Outcome

Intravenous albumin for spontaneous bacterial peritonitis and renal dysfunction in patients with cirrhosis-short review

2021 ◽  
Vol 5 (1) ◽  
pp. 01-03
Author(s):  
Marilena Stoian
Keyword(s):  
Renal Dysfunction ◽  
Spontaneous Bacterial Peritonitis ◽  
Cost Effective ◽  
Short Review ◽  
Decompensated Cirrhosis ◽  
Optimal Dosage ◽  
Bacterial Peritonitis ◽  
Beneficial Effects ◽  
Albumin Administration

Current clinical guidelines for albumin use in decompensated cirrhosis recommend the use of intravenous albumin infusions for management of ascites-related symptoms and paracentesis (removal of ascitic fluid) and for the management of spontaneous bacterial peritonitis (SBP), renal dysfunction and variceal bleeding. Routine albumin use is not recommended for the management of non-SBP infections. The aim of this review is to improve our understanding of the effects of albumin use in cirrhosis by reviewing the currently available and quantifying the effectiveness of intravenous albumin therapy to prevent specific cirrhosis complications, spontaneous bacterial peritonitis (SBP) and renal dysfunction. Long-term albumin administration to patients with decompensated cirrhosis improves survival, prevents complications, eases the management of ascites and reduces hospitalizations, thus being cost-effective. However, variant results indicate that further investigations are needed, aiming at confirming the beneficial effects of albumin, clarifying its optimal dosage and administration schedule and identify patients who would benefit most from long-term albumin administration.

scholarly journals Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease

2020 ◽  
Vol 19 (3) ◽  
pp. 147-158 ◽  
Author(s):  
Manuel Tufoni ◽  
Maurizio Baldassarre ◽  
Giacomo Zaccherini ◽  
Agnese Antognoli ◽  
Paolo Caraceni
Keyword(s):  
Biological Properties ◽  
Decompensated Cirrhosis ◽  
Systemic Effects ◽  
Plasma Expansion ◽  
Advanced Liver Disease ◽  
Albumin Administration ◽  
Target Disease ◽  
Clinical Benefits ◽  
Pleiotropic Properties

Abstract Purpose of Review Albumin administration is recommended to prevent or treat specific complications of decompensated cirrhosis based on its capacity to expand plasma volume. However, the molecule also has many other biological properties that are unrelated to the oncotic activity. The purpose of this review is to examine the hemodynamic and systemic effects of albumin administration in patients with decompensated cirrhosis. Recent Findings Besides plasma expansion, albumin appears to act against inflammation, facilitate immunocompetence, and improve cardiac and endothelial function, thus antagonizing critical steps in the pathophysiological cascade underlying decompensated cirrhosis. Summary Increasing knowledge of the pathophysiological mechanisms of the disease, as well the pleiotropic properties of the molecule, provides the rationale for considering albumin as a multi-target disease-modifying agent in decompensated cirrhosis. Both oncotic and non-oncotic properties likely concur with the clinical benefits of long-term albumin administration recently demonstrated in these patients.

scholarly journals Long-term administration of Tolvaptan to patients with decompensated cirrhosis

2020 ◽  
Vol 17 (7) ◽  
pp. 874-880 ◽  
Author(s):  
Kengo Kanayama ◽  
Tetsuhiro Chiba ◽  
Kazufumi Kobayashi ◽  
Keisuke Koroki ◽  
Toru Maruta ◽  
...  
Keyword(s):  
Decompensated Cirrhosis ◽  
Term Administration

Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 306-306
Author(s):  
Y. Kang ◽  
C. Yoo ◽  
B. Ryoo ◽  
H. Chang ◽  
J. Lee ◽  
...  
Keyword(s):  
Plasma Level ◽  
Gastrointestinal Stromal Tumors ◽  
Plasma Concentrations ◽  
Term Treatment ◽  
Albumin Concentration ◽  
Stromal Tumors ◽  
Long Term Treatment ◽  
The Mean ◽  
Median Interval

306 Background: Pharmacokinetic study in patients with gastrointestinal stromal tumors (GISTs) suggested that plasma concentrations of imatinib decrease following long-term exposure. We therefore measured changes in imatinib plasma trough levels (Cmin) after long-term exposure. Methods: Between November 2009 and May 2010, follow-up (FU) imatinib Cmin was measured in 65 patients who received the same dose of imatinib for at least 9 months after a previous baseline (BL) measurement. Total 244 blood samples were obtained (127 at BL and 117 at FU) and plasma level was measured by liquid chromatography-tandem mass spectrometry. Results: Median patient age was 54 years (range, 28–76 years) and 42 (64.6%) patients were male. Sixty-one (93.8%) patients were treated with 400 mg/day imatinib and 4 (6.2%) with 300 mg/day. The median interval from initiation of imatinib to BL test was 6.4 months (range, 0.5–66.6 months), and the median interval between BL and FU test was 13.1 months (range, 9.6–18.4 months). The mean ± standard deviation imatinib Cmin was significantly higher at FU than at BL (1442 ± 693 ng/mL vs 1221 ± 624 ng/mL, p<0.001). The mean inter- and intra-subject variabilities were 49.2% and 25.5%, respectively, at BL, and 44.2% and 20.4%, respectively, at FU. Multivariate analysis showed a significant correlation between the ratio of FU to BL imatinib Cmin and that of albumin (r=-0.397, p=0.001). In per-sample analysis, imatinib Cmin was significantly correlated with age, hemoglobin, albumin, creatinine clearance, previous major gastrectomy and time between initiation of imatinib and plasma level tests. Conclusions: Steady-state imatinib Cmin did not decrease but remained stable in most GIST patients during long-term treatment. Changes in imatinib Cmin were associated with changes in albumin concentration. Monitoring of imatinib Cmin only for concerns about time-dependent decreases in imatinib exposure is not necessary. [Table: see text]

scholarly journals Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

The Lancet ◽  
2018 ◽  
Vol 391 (10138) ◽  
pp. 2417-2429 ◽  
Author(s):  
Paolo Caraceni ◽  
Oliviero Riggio ◽  
Paolo Angeli ◽  
Carlo Alessandria ◽  
Sergio Neri ◽  
...  
Keyword(s):  
Randomised Trial ◽  
Decompensated Cirrhosis ◽  
Open Label ◽  
Albumin Administration
Sign in / Sign up

Export Citation Format

Share Document